| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | WARS; GAMMA-2; HWRS; IFI53; IFP53; TrpRS; WRS;;WARS1 |
| WB Predicted band size | 53 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human WARS1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于Flt3 Ligand(FL)抗体的代表性文献摘要简述(基于公开研究整理)：
---
1. **文献名称**：*"Structural basis of FLT3L recognition and hematopoietic activation"*
**作者**：Huang et al. (2022)
**摘要**：通过冷冻电镜解析Flt3L与受体FLT3的复合物结构，揭示抗体靶向阻断FLT3/FLT3L相互作用的分子机制，为开发抑制白血病细胞增殖的抗体药物提供结构基础。
---
2. **文献名称**：*"Anti-Flt3 antibody enhances dendritic cell vaccine efficacy by depleting regulatory T cells in tumor microenvironment"*
**作者**：Smith et al. (2018)
**摘要**：研究表明，抗Flt3抗体通过耗竭肿瘤微环境中的调节性T细胞(Tregs)，显著增强树突状细胞疫苗的抗肿瘤免疫效果，为联合免疫治疗提供新策略。
---
3. **文献名称**：*"A neutralizing anti-Flt3 ligand monoclonal antibody suppresses murine AML progression"*
**作者**：Kikushige & Miyamoto (2015)
**摘要**：开发了一种中和性抗Flt3L单克隆抗体，在急性髓系白血病(AML)小鼠模型中证实其可通过阻断Flt3L信号通路抑制白血病干细胞自我更新，延缓疾病进展。
---
**注**：以上内容为简化概括，实际文献需通过PubMed或Sci-Hub等平台按标题/作者检索获取全文。如需具体DOI或期刊信息可进一步补充说明。
Flt3 ligand (Flt3L) is a key cytokine involved in the regulation of hematopoietic stem cells and immune cell development. It binds to the Fms-like tyrosine kinase 3 (Flt3) receptor, a type III receptor tyrosine kinase expressed on early hematopoietic progenitors and dendritic cells (DCs). Signaling through Flt3/Flt3L promotes the proliferation, differentiation, and survival of these cells, playing critical roles in both innate and adaptive immunity. Dysregulation of this pathway is linked to hematologic malignancies, such as acute myeloid leukemia (AML), where Flt3 mutations are common.
Antibodies targeting Flt3 ligand are essential tools for studying its biological functions and therapeutic potential. These antibodies can block Flt3L-Flt3 interactions, enabling researchers to investigate the cytokine’s role in hematopoiesis, DC maturation, and immune responses. Monoclonal antibodies (mAbs) against Flt3L are widely used in assays like ELISA, Western blot, and flow cytometry to quantify ligand expression or inhibit its activity in vitro and in vivo. Additionally, therapeutic anti-Flt3L antibodies are being explored to modulate immune responses in conditions like cancer or autoimmune diseases. For instance, blocking Flt3L may suppress DC-mediated T-cell activation, offering a strategy to manage inflammation. Conversely, enhancing Flt3L signaling could boost DC production for cancer immunotherapy.
Overall, Flt3L antibodies serve as vital reagents in basic research and drug development, bridging insights into immune regulation and targeted therapies.
×
